株式会社カワチ薬品 2025年3月期通期業績予想の修正に関するお知らせ

This document is a notification from Kawachi Pharmaceutical Co., Ltd. regarding the revision of its consolidated earnings forecast for the fiscal year ending March 2025, announced on October 25, 2024. The revised forecast includes sales of 289 billion yen, operating profit of 7.8 billion yen, ordinary profit of 8.7 billion yen, and net profit attributable to shareholders of 5.4 billion yen. The revision is attributed to a decline in sales due to the continued sluggishness of infection control products, despite a recovery in beauty-related merchandise. Additionally, while labor costs and utility expenses increased, selling, general and administrative expenses were restrained, leading to profits falling short of the initial plan.